{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:04:36Z","timestamp":1778313876075,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The recent improvements in anti-cancer therapy following first-line treatment can potentially impact post-progression survival. We evaluated the factors that influence post-progression survival in advanced recurrent ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eighty-nine patients who underwent first-line treatment between June 2005 and December 2017 were included. The post-progression survival was defined as the difference between overall survival and initial progression-free survival. The effects of age, histology, stage, optimal surgery, secondary debulking surgery, bevacizumab administration, platinum sensitivity, and olaparib maintenance in recurrence were compared and independent risk factors were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median follow-up duration was 60.0\u00a0months (range: 2\u2013181). Platinum-sensitive recurrence had longer post-progression survival than platinum-resistant (P\u00a0&amp;lt;\u00a00.001). Inclusion of bevacizumab in first-line treatment did not produce a significant difference in post-progression survival (P\u00a0=\u00a00.462). Secondary debulking surgery (P\u00a0=\u00a00.013), bevacizumab administration (P\u00a0&amp;lt;\u00a00.001), and olaparib maintenance (P\u00a0=\u00a00.001) during recurrence increased post-progression survival. In multivariate analysis, histologies other than serous or endometrioid (hazard ratio\u00a0=\u00a02.389; 95% confidence interval\u00a0=\u00a01.200\u20134.754; P\u00a0=\u00a00.013) and non-bevacizumab usage in recurrence (hazard ratio\u00a0=\u00a04.484; 95% confidence interval\u00a0=\u00a01.939\u201310.370; P\u00a0&amp;lt;\u00a00.001) were independently correlated with poorer prognosis. Bevacizumab administration beyond progressive disease elicited improved post-progression survival (P\u00a0&amp;lt;\u00a00.001). In patients receiving bevacizumab in first-line treatment, exclusion of bevacizumab in the recurrent therapy (hazard ratio\u00a0=\u00a05.507; 95% confidence interval\u00a0=\u00a02.301\u201312.124; P\u00a0&amp;lt;\u00a00.001) was independently correlated with poorer prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The continuous use of bevacizumab beyond progressive disease improves post-progression survival suggesting its important role in first-line and recurrence treatment for ovarian cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyab105","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:12:16Z","timestamp":1625598736000},"page":"1407-1415","source":"Crossref","is-referenced-by-count":2,"title":["The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer"],"prefix":"10.1093","volume":"51","author":[{"given":"Shintaro","family":"Yanazume","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ushiwaka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1920-9405","authenticated-orcid":false,"given":"Shinichi","family":"Togami","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kamio","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"2021083104305465200_ref1","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"2021083104305465200_ref2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"2021083104305465200_ref3","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021083104305465200_ref4","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021083104305465200_ref5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2021083104305465200_ref6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021083104305465200_ref7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2016.05.011","article-title":"Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer","volume":"142","author":"Husain","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021083104305465200_ref8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jjco\/hyaa140","article-title":"A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer","volume":"51","author":"Nanki","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2021083104305465200_ref9","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.21873\/anticanres.14533","article-title":"Continuous administration of bevacizumab after disease progression in recurrent ovarian cancer: a retrospective observational study","volume":"40","author":"Tanigawa","year":"2020","journal-title":"Anticancer Res"},{"key":"2021083104305465200_ref10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305465200_ref11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2021083104305465200_ref12","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdr487","article-title":"Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer","volume":"23","author":"Hayashi","year":"2012","journal-title":"Ann Oncol"},{"key":"2021083104305465200_ref13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv133","article-title":"Detecting overall survival benefit derived from survival postprogression rather than progression-free survival","author":"Morita","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305465200_ref14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.7150\/jca.17664","article-title":"Overall survival and post-progression survival are potent endpoint in phase III trials of second\/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer","volume":"9","author":"Shimokawa","year":"2018","journal-title":"J Cancer"},{"key":"2021083104305465200_ref15","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.v18is2.939","article-title":"Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective","volume":"18","author":"Oza","year":"2011","journal-title":"Curr Oncol"},{"key":"2021083104305465200_ref16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18939","article-title":"Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis","volume":"3","author":"Paoletti","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2021083104305465200_ref17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"2021083104305465200_ref18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4505-4","article-title":"An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023","volume":"18","author":"Shoji","year":"2018","journal-title":"BMC Cancer"},{"key":"2021083104305465200_ref19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021083104305465200_ref20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/cncr.29893","article-title":"Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"key":"2021083104305465200_ref21","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/annonc\/mdw316","article-title":"Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent\/metastatic breast cancer","volume":"27","author":"Vrdoljak","year":"2016","journal-title":"Ann Oncol"},{"key":"2021083104305465200_ref22","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/9\/1407\/40082862\/hyab105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/9\/1407\/40082862\/hyab105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T04:31:18Z","timestamp":1630384278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/9\/1407\/6317403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,7,7]]},"published-print":{"date-parts":[[2021,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab105","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,7,7]]}}}